睿知中国疾病研究地图
候选清单0

上海上海交通大学医学院

上海市第一人民医院

Shanghai General Hospital

在本站收录的 53 种疾病中,这家医院列在其中 20 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海市第一人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma36 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer27 篇牵头论文牵头 1 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma5 篇牵头论文
  7. 骨肉瘤Osteosarcoma24 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma2 篇牵头论文
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  12. 再生障碍性贫血Aplastic anaemia0 篇牵头论文
  13. 血友病 AHaemophilia A0 篇牵头论文
  14. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  15. 大动脉炎Takayasu arteritis1 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  18. IgA 肾病IgA nephropathy0 篇牵头论文
  19. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  20. Leber 遗传性视神经病变Leber hereditary optic neuropathy2 篇牵头论文

未列出的收录疾病:肝母细胞瘤、尤文肉瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

上海有 10 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术诱导/同步化疗影像与人工智能
论文中的科室放疗科耳鼻喉/头颈外科普外/肝胆胰外科
牵头的论文5
  1. Combination of pan-immune-inflammation value and frailty index predicts the outcomes of elderly nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.2025Future oncology (London, England)
  2. PICK1 inhibits the malignancy of nasopharyngeal carcinoma and serves as a novel prognostic marker.2024Cell death & disease免费全文
  3. Identification of shared immune infiltration characteristic molecules in dermatomyositis and nasopharyngeal carcinoma using bioinformatics: Traits in dermatomyositis and nasopharyngeal cancer.2024Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)免费全文
  4. Hypoxia-induced degradation of PICK1 by RBCK1 promotes the proliferation of nasopharyngeal carcinoma cells.2023Life sciences
  5. Prognostic significance of MRI-based late-course tumor volume in locoregionally advanced nasopharyngeal carcinoma.2022Radiation oncology (London, England)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  2. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)2
  1. Genistein and chlorin E6-loaded versatile nanoformulation for remodeling the hypoxia-related tumor microenvironment and boosting photodynamic therapy in nasopharyngeal carcinoma treatment2025Advanced Composites and Hybrid Materials论文
  2. MRI-Based Quantification of Intratumoral Heterogeneity in Locally Advanced Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-02
    登记号
    NCT06304350

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 36 篇,占 0.2%。

牵头论文
36
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 6620222023: 7720232024: 9920242025: 442025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
    分期
    早期I期
    开始
    2024-11
    登记号
    NCT06652243

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:上海市第一人民医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现手术与肝移植
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文36
  1. A novel prognostic framework for HBV-infected hepatocellular carcinoma: insights from ferroptosis and iron metabolism proteomics.2025Briefings in bioinformatics免费全文
  2. Exosome-derived SLC12A2-DT promotes macrophage M2 polarization-mediated hepatocellular carcinoma progression.2025International immunopharmacology
  3. vtRNA1-1 drives regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis.2025International journal of biological macromolecules
  4. CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype.2025Journal of experimental & clinical cancer research : CR免费全文
  5. Circ_0098823 binding with IGF2BP3 regulates DNM1L stability to promote metastasis of hepatocellular carcinoma via mitochondrial fission.2024Apoptosis : an international journal on programmed cell death
  6. Bilateral diffuse uveal melanocytic proliferation secondary to combined hepatocellular-cholangiocarcinoma.2024Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
  7. 99mTc-Labeled D-Type PTP as a Plectin-Targeting Single-Photon Emission Computed Tomography Probe for Hepatocellular Carcinoma Imaging.2024Bioconjugate chemistry
  8. Influence of recipient KRAS gene rs712 polymorphisms on the overall survival rate of hepatocellular carcinoma after hepatic transplantation.2024Clinical and experimental medicine免费全文
  9. Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.2024Experimental cell research
  10. THAP3 recruits SMYD3 to OXPHOS genes and epigenetically promotes mitochondrial respiration in hepatocellular carcinoma.2024FEBS letters
  11. Multi-omics analysis reveals mechanism of Schisandra chinensis lignans and acteoside on EMT in hepatoma cells via ERK1/2 pathway.2024Functional & integrative genomics
  12. Endoscopic ultrasound for the diagnosis and treatment of primary hepatocellular carcinoma.2024Journal of digestive diseases
  13. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.2024The journal of gene medicine
  14. HCC: RNA-Sequencing in Cirrhosis.2023Biomolecules免费全文
  15. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.2023Cancer reports (Hoboken, N.J.)免费全文
  16. A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations.2023Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  17. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.2023Frontiers in immunology免费全文
  18. Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma.2023Human cell
  19. Characterization of the Clinical Significance and Immunological Landscapes of a Novel TMEMs Signature in Hepatocellular Carcinoma and the Contribution of TMEM201 to Hepatocarcinogenesis.2023International journal of molecular sciences免费全文
  20. Baseline ALBI Grade Predicts Benefits After Splenectomy for Cirrhotic Patients with Hypersplenism.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract免费全文
  21. Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway.2022Annals of hepatology
  22. SLC38A6, regulated by EP300-mediated modifications of H3K27ac, promotes cell proliferation, glutamine metabolism and mitochondrial respiration in hepatocellular carcinoma.2022Carcinogenesis
  23. Influences of Oral Administration of Probiotics on Posthepatectomy Recovery in Patients in Child-Pugh Grade.2022Computational and mathematical methods in medicine免费全文
  24. Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  25. The oncogenic miR-27a/BTG2 axis promotes obesity-associated hepatocellular carcinoma by mediating mitochondrial dysfunction.2022Neoplasma
  26. Clinical application of deep learning and radiomics in hepatic disease imaging: a systematic scoping review.2022The British journal of radiology免费全文
  27. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC.2021Aging免费全文
  28. Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma.2021Aging免费全文
  29. Estradiol is significantly associated with prognosis in non-surgical liver cancer patients: from bench to bedside.2021Aging免费全文
  30. Recipient C7 rs9292795 genotype and the risk of hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population.2021BMC cancer免费全文
  31. Autophagy, an accomplice or antagonist of drug resistance in HCC?2021Cell death & disease免费全文
  32. USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma.2021Cellular signalling
  33. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.2021Journal of experimental & clinical cancer research : CR免费全文
  34. Linc-SCRG1 accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2.2021Journal of experimental & clinical cancer research : CR免费全文
  35. Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.2021Oncogene
  36. The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma正在招募NCT06652243牵头方早期I期2024-11 启动
  2. Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation状态不明NCT01125020牵头方(推断)不分期2008-12 启动
  3. Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids已完成NCT01137084牵头方(推断)不分期2005-01 启动
  4. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.3%。

牵头论文
27
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 5520222023: 5520232024: 6620242025: 552025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
    分期
    II期
    开始
    2022-09
    登记号
    NCT05536102

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市第一人民医院上海

  2. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜腹膜转移与晚期营养与康复
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科肿瘤内科
牵头的论文27
  1. Hypoxia-Induced circPRELID2 Promotes Gastric Cancer Metastasis by Facilitating ZEB2 Translation via PCBP1 O-GlcNAcylation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. USP47 enhances NRP1-mediated angiogenesis to promote gastric cancer progression.2025Biochimica et biophysica acta. Molecular cell research
  3. FTO-Mediated m6A Demethylation of CCL2 Promotes Gastric Cancer Progression via Autophagy and Oxidative Stress Regulation.2025Digestive diseases and sciences
  4. Exploration of the pharmacological substance basis and efficacy evaluation of fufang she-she-cao (Hedyotis diffusa formula) in repressing gastric cancer.2025Journal of ethnopharmacology
  5. A comprehensive study on the radiomic score derived from perineural invasion in gastric cancer and its correlation with the overall survival of patients.2025La Radiologia medica
  6. Insights into the role of glycosyltransferase in the targeted treatment of gastric cancer.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. Regulation of regulatory T cells and tumor-associated macrophages in gastric cancer tumor microenvironment.2024Cancer medicine免费全文
  8. A deep learning model based on magnifying endoscopy with narrow-band imaging to evaluate intestinal metaplasia grading and OLGIM staging: A multicenter study.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  9. A predictive nomogram developed and validated for gastric cancer patients with triple-negative tumor markers.2024Future oncology (London, England)
  10. The role of microbiota in gastric cancer: A comprehensive review.2024Helicobacter
  11. DNA methyltransferase 3a-induced hypermethylation of the fructose-1,6-bisphosphatase-2 promoter contributes to gastric carcinogenesis.2024Molecular biology reports
  12. Five EMT-related genes signature predicts overall survival and immune environment in microsatellite instability-high gastric cancer.2023Cancer medicine免费全文
  13. TCL1A acts as a tumour suppressor by modulating gastric cancer autophagy via miR-181a-5p-TCL1A-Akt/mTOR-c-MYC loop.2023Carcinogenesis
  14. Novel KDM2B/SAV1 Signaling Pathway Promotes the Progression of Gastric Cancer.2023Genetics research免费全文
  15. Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer.2023Nature communications免费全文
  16. The features of gastric epithelial reactive hyperplastic lesions under magnifying endoscopy combined with narrow-band imaging.2023Scandinavian journal of gastroenterology
  17. The kinase activity of integrin-linked kinase regulates cellular senescence in gastric cancer.2022Cell death & disease免费全文
  18. Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.2022Digestive diseases and sciences
  19. Endoscopic extraction of a gastric submucosal foreign body after precise location with endoscopic ultrasound combined with endoscopic submucosal dissection.2022Endoscopy
  20. Complete loss of miR-200 family induces EMT associated cellular senescence in gastric cancer.2022Oncogene免费全文
  21. Progress and application of epitranscriptomic m6A modification in gastric cancer.2022RNA biology免费全文
  22. High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.2021Annals of palliative medicine
  23. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer.2021Biochimica et biophysica acta. Reviews on cancer
  24. ITIH4 is a novel serum biomarker for early gastric cancer diagnosis.2021Clinica chimica acta; international journal of clinical chemistry
  25. MEF2A-mediated lncRNA HCP5 Inhibits Gastric Cancer Progression via MiR-106b-5p/p21 Axis.2021International journal of biological sciences免费全文
  26. HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis.2021Journal of experimental & clinical cancer research : CR免费全文
  27. Plexiform fibromyxoma: a clinicopathological and immunohistochemical analysis of two cases with a literature review.2021The Journal of international medical research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)正在招募NCT05536102牵头方II期2022-09 启动
  2. Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer状态不明NCT02640898牵头方不分期2015-12 启动
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  5. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  6. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  7. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  8. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  9. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  10. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  11. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer已完成NCT04053205研究中心I/II期2019-11 启动
  12. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  13. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  14. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  15. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  16. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 11 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 4.8%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 222025

上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 1.1%。

牵头论文
24
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 9920222023: 1120232024: 5520242025: 332025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文24
  1. Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma.2025Cell reports. Medicine
  2. Prediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS Cohort.2025JCO precision oncology
  3. Etoposide activates CD8+ T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signaling.2025Journal for immunotherapy of cancer
  4. Enhanced Osteosarcoma Immunotherapy via CaCO3 Nanoparticles: Remodeling Tumor Acidic and Immune Microenvironment for Photodynamic Therapy.2024Advanced healthcare materials
  5. Engineering Bimetallic Polyphenol for Mild Photothermal Osteosarcoma Therapy and Immune Microenvironment Remodeling by Activating Pyroptosis and cGAS-STING Pathway.2024Advanced healthcare materials
  6. KDELR1 regulates chondrosarcoma drug resistance and malignant behavior through Intergrin-Hippo-YAP1 axis.2024Cell death & disease
  7. Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma.2024Cellular oncology (Dordrecht, Netherlands)
  8. Eurycomanone inhibits osteosarcoma growth and metastasis by suppressing GRP78 expression.2024Journal of ethnopharmacology
  9. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway.2023European journal of pharmacology
  10. Lotus Seedpod-Inspired Crosslinking-Assembled Hydrogels Based on Gold Nanoclusters for Synergistic Osteosarcoma Multimode Imaging and Therapy.2022ACS applied materials & interfaces
  11. Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  12. Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis.2022Cancer biology & medicine
  13. Feasibility and preliminary efficacy of tantalum components in the management of acetabular reconstruction following periacetabular oncologic resection in primary malignancies.2022European journal of medical research
  14. Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.2022Frontiers in immunology
  15. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.2022Nature communications
  16. CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma.2022Oncogene
  17. Correlation between Patient-Derived Xenograft Modeling and Prognosis in Osteosarcoma.2022Orthopaedic surgery
  18. Revision surgeries for tumor endoprostheses around the knee joint: a mid-long-term follow-up of 20 cases.2022World journal of surgical oncology
  19. Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients.2021Aging
  20. Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis.2021Cancer letters
  21. Osteosarcoma-derived exosomal miR-501-3p promotes osteoclastogenesis and aggravates bone loss.2021Cellular signalling
  22. Identification of two immune subtypes in osteosarcoma based on immune gene sets.2021International immunopharmacology
  23. The disulfiram/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS/JNK signalling pathway.2021Journal of biochemistry
  24. MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma.2021Journal of experimental & clinical cancer research : CR
中文论文(未计入)1
  1. [An exploratory clinical study of the efficacy and safety of tumor-infiltrating lymphocytes in the treatment of metastatic osteosarcoma].2022Zhonghua yi xue za zhi
早期论文(2016–2020 年)28
  1. Costunolide inhibits osteosarcoma growth and metastasis via suppressing STAT3 signal pathway.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. circ_ARF3 regulates the pathogenesis of osteosarcoma by sponging miR-1299 to maintain CDK6 expression.2020Cellular signalling
  3. Conditioned medium of the osteosarcoma cell line U2OS induces hBMSCs to exhibit characteristics of carcinoma-associated fibroblasts via activation of IL-6/STAT3 signalling.2020Journal of biochemistry
  4. Local delivery of sunitinib and Ce6 via redox-responsive zwitterionic hydrogels effectively prevents osteosarcoma recurrence.2020Journal of materials chemistry. B
  5. Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma.2020Nanomedicine : nanotechnology, biology, and medicine
  6. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.2019Biochimica et biophysica acta. Molecular basis of disease
  7. Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.2019Bioscience reports
  8. Antitumor activity of Raddeanin A is mediated by Jun amino-terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma.2019Cancer science
  9. Attenuation of STAT3 Phosphorylation Promotes Apoptosis and Chemosensitivity in Human Osteosarcoma Induced by Raddeanin A.2019International journal of biological sciences
  10. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.2019International journal of cancer
  11. Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies.2019Journal of cellular and molecular medicine
  12. CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma.2019Journal of experimental & clinical cancer research : CR
  13. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.2018Biochimica et biophysica acta. Molecular basis of disease
  14. Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma.2018International journal of oncology
  15. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.2018Journal of experimental & clinical cancer research : CR
  16. Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications.2018Stem cell research & therapy
  17. Sarcoma-Targeting Peptide-Decorated Polypeptide Nanogel Intracellularly Delivers Shikonin for Upregulated Osteosarcoma Necroptosis and Diminished Pulmonary Metastasis.2018Theranostics
  18. NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.2017Cell death & disease
  19. Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma.2017Free radical biology & medicine
  20. Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.2017Journal of cellular and molecular medicine
  21. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.2017Oncogene
  22. Long non-coding RNAs in osteosarcoma.2017Oncotarget
  23. [Effect of rapamycin and chloroquine on osteosarcoma].2017Zhonghua yi xue za zhi
  24. MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma.2016Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  25. Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo.2016Cell death & disease
  26. Bioinformatics analysis of differentially expressed pathways related to the metastatic characteristics of osteosarcoma.2016International journal of molecular medicine
  27. CD151-mediated adhesion is crucial to osteosarcoma pulmonary metastasis.2016Oncotarget
  28. Gelsolin promotes cell growth and invasion through the upregulation of p-AKT and p-P38 pathway in osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients即将招募NCT07142863牵头方II期2025-08 启动
  2. A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors状态不明NCT06171282牵头方(推断)早期I期2023-07 启动
  3. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动
  4. Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas已暂停NCT07052383研究中心I期2025-11 启动
  5. Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma状态不明NCT06117878研究中心早期I期2022-09 启动
  6. Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)已完成NCT05277480研究中心II期2022-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Up-regulation of LYAR blocks Myc-induced cell death.2017Cell cycle (Georgetown, Tex.)

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 9 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL状态不明NCT05379569牵头方IV期2022-05 启动
  2. Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL已完成NCT03919526牵头方I期2019-08 启动
  3. Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia状态不明NCT03798509研究中心I期2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年没有牵头再生障碍性贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 3 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia已完成NCT02745717牵头方IV期2016-01 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 9 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
中文论文(未计入)1
  1. Acquired hemophilia A secondary to cholangiocarcinoma: A case report and literature review.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 8 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
牵头的论文1
  1. m6A modification regulates lung fibroblast-to-myofibroblast transition through modulating KCNH6 mRNA translation.2021Molecular therapy : the journal of the American Society of Gene Therapy
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Trial of HRS-9813 in Healthy Subjects已完成NCT06821464研究中心I期2025-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Progress in diagnosis and therapy of extrahepatic manifestations of cholestatic liver diseases].2016Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

上海有 3 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文2
  1. Cognitive Impairment in Phenotypic Leber Hereditary Optic Neuropathy Caused by Mutation in Nuclear Gene NDUFAF5.2024Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  2. Rapid and Sensitive Diagnosis of Leber Hereditary Optic Neuropathy Variants Using CRISPR/Cas12a Detection.2023The Journal of molecular diagnostics : JMD

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海市第一人民医院

Shanghai General Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Shanghai First People's Hospital; Jiading Branch of Shanghai General Hospital; Shanghai General Hospital Affiliated to Shanghai Jiaotong University; Shanghai General Hospital/Faculty of Basic Medicine; Shanghai General Hospital of Nanjing Medical University; Shanghai Jiaotong University Shanghai General Hospital; Shanghai General Hospital Affiliated to Nanjing Medical University; Jiading Branch of Shanghai First People's Hospital

提出更正下载数据